首页> 中文期刊> 《肿瘤基础与临床》 >全身化疗联合腹腔热灌注化疗并射频热疗治疗晚期卵巢癌

全身化疗联合腹腔热灌注化疗并射频热疗治疗晚期卵巢癌

             

摘要

Objective To study the efficacy of chemotherapy plus hyperthermic intraperitoneal chemotherapy and radiofrequency thermotherapy in the treatment of advanced ovarian cancer. Methods Sixty patients with advanced ovarian cancer were randomly divided into two groups. Thirty patients of the control group received the chemotherapy plus intraperitoneal chemotherapy,and 30 patients of the observation group received the chemotherapy plus hyper-thermic intraperitoneal chemotherapy and radiofrequency thermotherapy. Results The response rate of the observa-tion group(73. 3%)was higher than that of the control group(40. 0%)(P﹤0. 05). The ascites-control response rate of the observation group(77. 3%)was higher than that of the control group(45. 0%)(P﹤0. 05). There was no significant statistical difference in the toxicities between the two groups(P﹥0. 05). Conclusion Chemotherapy plus hyperthermic intraperitoneal chemotherapy and radiofrequency thermotherapy is effect and safe in the treatment of advanced ovarian cancer.%目的:评价全身化疗联合腹腔热灌注化疗并射频热疗治疗晚期卵巢癌的效果。方法将60例晚期卵巢癌患者随机分为2组,每组30例,对照组30例接受全身化疗联合腹腔灌注化疗,而观察组30例接受全身化疗联合腹腔热灌注化疗并射频热疗。结果观察组有效率为73.3%,高于对照组的40.0%( P﹤0.05);观察组腹水减少有效率为77.3%,高于对照组的45.0%(P﹤0.05)。2组毒副反应相近,且均为轻度。结论全身化疗联合腹腔热灌注化疗并射频热疗治疗晚期卵巢癌的效果治疗晚期卵巢癌安全有效。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号